FINWIRES · TerminalLIVE
FINWIRES

OR Royalties Up 1% In US Premarket As Buys Precious Metals Stream on Canadian Copper's New Brunswick Assets

-- OR Royalties (OR.TO) was at last look up 1% in US premarket trade after the company said it is acquiring a precious metals stream on Canadian Copper's (CCI.CN) New Brunswick assets for US$28.0 million.

A statement noted the assets comprise the Murray Brook properties and the Caribou property, and include the Caribou Processing Plant.

OR Royalties will pay US$5.0 million cash upon closing, with US$23.0 million funded quarterly in line with project construction budgets, a statement said. A US$35.0 million concentrate prepayment facility has been provided by Ocean Partners UK, securing the full construction financing required to advance the project into commercial production.

Concurrent with closing, OR Royalties will subscribe to US$4.0 million in Canadian Copper shares at C$0.75 apiece.

Canadian Copper will deliver refined silver and gold equal to 20% of the payable silver and gold in concentrate or any other product for the life of mine to OR Royalties. This does not include payable gold from Murray Brook.

"Canadian Copper's Murray Brook Project checks all of our strategic boxes; the integration of Murray Brook and the Caribou Complex creates a premier brownfield polymetallic project with significant precious metals credits in a Tier-1 mining jurisdiction. Thanks to existing infrastructure and strong alignment with local stakeholders, the project benefits from a significantly accelerated development timeline. We are excited to partner with Canadian Copper as they advance toward a mine-and-mill restart, which is expected to deliver high-margin GEOs to OR Royalties before the end of the decade," said OR Royalties chief executive Jason Attew.

OR Royalties shares closed down $0.12, to $54.44 on Monday on the Toronto Stock Exchange.

相关文章

Australia

再生元公司称,FDA已加速批准其治疗遗传性听力损失的疗法

再生元公司(Regeneron,股票代码:REGN)周四宣布,美国食品药品监督管理局(FDA)已加速批准其治疗OTOF基因相关听力损失的药物Otarmeni用于治疗儿童和成人患者。 根据一份声明,FDA的批准基于正在进行的Chord试验。该试验显示,20名受试者中有16名在纯音测听评估中听力有所改善,其中14名表现出听觉脑干反应。 再生元公司表示,Otarmeni的持续批准可能取决于Chord试验验证性部分中临床获益的验证和描述。 该公司表示,将为美国符合临床条件的患者免费提供Otarmeni。 该公司股价周四上涨2%。Price: $761.47, Change: $+14.89, Percent Change: +1.99%

$REGN
Sectors

行业动态:医疗保健

周四下午,医疗保健类股下跌,纽约证券交易所医疗保健指数下跌0.5%,道富医疗保健精选行业SPDR ETF (XLV)下跌0.7%。 iShares生物技术ETF (IBB)下跌1.9%。 公司新闻方面,赛默飞世尔科技(TMO)周四上调了全年业绩预期,原因是其第一季度业绩强于预期,尽管内生增长低于分析师预期。该公司股价下跌10.9%。

$TMO
Research

美国银行称,德州仪器将受益于工业复苏和数据中心需求增长。

美国银行周四发布的一份报告指出,德州仪器 (TXN) 有望受益于工业复苏,尤其是在航空航天/国防、数据中心需求以及其美国本土制造业务带来的收益增长。 该券商还表示,随着德州仪器逐步摆脱大规模资本支出周期,其自由现金流有望更加强劲。报告还指出,德州仪器能够利用过去三年在美国晶圆厂的巨额资本支出,在“资源受限”的芯片市场中抢占市场份额。 美国银行还表示,看好德州仪器在直流电源领域的定位,该公司“在机架级产品中占据主导地位,并且随着架构向更高电压/更高功率密度系统发展,其专用插座业务也呈现增长势头”。 然而,美国银行指出,持续的地缘政治动荡仍然是整个行业面临的风险,但补充说,德州仪器历来具有相对更强的防御性。 美国银行将该股评级从“中性”上调至“买入”,并将目标价从 235 美元上调至 320 美元。Price: $283.62, Change: $+47.31, Percent Change: +20.02%

$TXN